Molecular Templates hitches with Alnylam on RNAi delivery; PolyPid introduced new drug carriers;

> Molecular Templates a biopharmaceutical company developing what it calls a new class of small biologic therapies called Engineered Toxin Bodies has entered into a research collaboration with Alnylam Pharmaceuticals, which will  evaluate and develop Molecular Templates' technology for targeted delivery of RNAi therapies. No financial terms were disclosed. Release

> PolyPid has introduced a new family of drug carriers based on a melding of two drug delivery systems: polymers and lipid-based systems. The PolyPid carrier carrier can be tailored to small molecules, peptides, protein and nucleic acids-based drugs. Story

> Acrux receives boost from Europe for drug delivery technology for dogs. Item

> Independent clinical study validates Nanologica's new drug carrier material for oral use. Nanologica release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.